Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 7/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.35 |
| ▸ | F12 | P00748 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25684834 | 0.89 | PARP1 (0.42) | PARP1HTR6F12CYP3A4 | |
| SCHEMBL21162344 | 0.89 | PARP1 (0.42) | PARP1HTR6MCHR1CYP3A4 | |
| SCHEMBL25687796 | 0.80 | HTR6 (0.52) | HTR6HTR2AHTR2CKDM4EALOX15 | |
| SCHEMBL16610030 | 0.79 | MCHR1 (0.51) | MCHR1HTR2AHTR2CCYP3A4KDM4E | |
| SCHEMBL21162350 | 0.78 | CYP3A4 (0.48) | PARP1CYP3A4 | |
| Hydrochloric Acid SCHEMBL17940522 | 0.78 | KDM4E (0.51) | MCHR1HTR2AHTR2CCYP3A4KDM4E | |
| SCHEMBL5375896 | 0.75 | HTR6 (0.41) | PARP1HTR6MCHR1F12CYP3A4 | |
| SCHEMBL25685210 | 0.74 | PARP1 (0.33) | PARP1MCHR1F12 | |
| SCHEMBL25685891 | 0.73 | HTR6 (0.40) | PARP1HTR6HTR2AHTR2CCYP3A4 | |
| SCHEMBL25685343 | 0.73 | HTR2C (0.40) | HTR6HTR2AHTR2CCYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255976-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | AC IMMUNE SA (CH) | 2023-08-17 | — | — | US | disclosed |
| US-11684625-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates | AC IMMUNE SA (CH) | 2023-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255976-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | MAPT, MAP1LC3A, MAP1LC3B | PARP1 2974/4885HTR6 2414/4885MCHR1 2694/4885 |
| US-11684625-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates | MAPT, PSEN2, PSEN1 | PARP1 3154/4885HTR6 2460/4885MCHR1 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.